SG166001A1 - Methods of generating and screening for proteases with altered specificity - Google Patents
Methods of generating and screening for proteases with altered specificityInfo
- Publication number
- SG166001A1 SG166001A1 SG200704897-8A SG2007048978A SG166001A1 SG 166001 A1 SG166001 A1 SG 166001A1 SG 2007048978 A SG2007048978 A SG 2007048978A SG 166001 A1 SG166001 A1 SG 166001A1
- Authority
- SG
- Singapore
- Prior art keywords
- proteases
- methods
- generating
- screening
- altered specificity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41538802P | 2002-10-02 | 2002-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG166001A1 true SG166001A1 (en) | 2010-11-29 |
Family
ID=32069849
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200704897-8A SG166001A1 (en) | 2002-10-02 | 2003-10-02 | Methods of generating and screening for proteases with altered specificity |
SG2009070467A SG188669A1 (en) | 2002-10-02 | 2003-10-02 | Method of generating and screening for proteases with altered specificity |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2009070467A SG188669A1 (en) | 2002-10-02 | 2003-10-02 | Method of generating and screening for proteases with altered specificity |
Country Status (13)
Country | Link |
---|---|
US (2) | US20040146938A1 (zh) |
EP (3) | EP1608947A4 (zh) |
JP (3) | JP5376747B2 (zh) |
KR (3) | KR20100109969A (zh) |
CN (2) | CN101124484A (zh) |
AU (2) | AU2003282724B2 (zh) |
CA (1) | CA2501295A1 (zh) |
MX (1) | MXPA05003493A (zh) |
NO (1) | NO20052096L (zh) |
NZ (2) | NZ590187A (zh) |
SG (2) | SG166001A1 (zh) |
WO (1) | WO2004031733A2 (zh) |
ZA (1) | ZA200502867B (zh) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060024289A1 (en) * | 2002-10-02 | 2006-02-02 | Ruggles Sandra W | Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases |
US7939304B2 (en) | 2002-10-02 | 2011-05-10 | Catalyst Biosciences, Inc. | Mutant MT-SP1 proteases with altered substrate specificity or activity |
ZA200502867B (en) * | 2002-10-02 | 2007-09-26 | Catalyst Biosciences Inc | Methods of generating and screening for proteases with altered specificity |
US7824885B2 (en) * | 2003-08-06 | 2010-11-02 | University Of Maryland, College Park | Engineered proteases for affinity purification and processing of fusion proteins |
AU2005244271B2 (en) | 2004-04-12 | 2010-04-08 | Vertex Pharmaceuticals Incorporated | Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1 |
WO2005100556A2 (en) * | 2004-04-12 | 2005-10-27 | Catalyst Biosciences | Cleavage of vegf and vegf receptor by wild-type and mutant proteases |
JP2006117594A (ja) * | 2004-10-22 | 2006-05-11 | Shiseido Co Ltd | 活性型カスパーゼ−14特異的抗体及びその作成方法 |
PL1866328T3 (pl) | 2005-03-22 | 2011-05-31 | Rohto Pharma | Peptydy zwiększające wytwarzanie kolagenu lub kwasu hialuronowego |
MX2008004693A (es) * | 2005-10-21 | 2008-09-03 | Catalyst Biosciences Inc | Proteasas modificadas que inhiben la activacion del complemento. |
EP2423305A1 (en) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
DK2046951T5 (da) * | 2006-07-05 | 2012-01-23 | Catalyst Biosciences Inc | Proteasesreeningsmetoder og proteaser identificeret dermed |
EP2147096B1 (en) * | 2007-04-13 | 2015-03-25 | Catalyst Biosciences, Inc. | Modified factor VII polypeptides and uses thereof |
TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
DK2337849T3 (en) | 2008-09-15 | 2018-10-01 | Uniqure Biopharma B V | FACTOR IX POLYPEPTIME MUTANT, APPLICATIONS THEREOF AND METHOD OF PRODUCING THEREOF |
CA2764775C (en) * | 2009-06-26 | 2019-02-26 | University Of Florida Research Foundation, Inc. | Rapid bed-side measurement of neutrophil elastase activity in biological fluids |
WO2011038114A1 (en) * | 2009-09-23 | 2011-03-31 | Potomac Affinity Proteins, Inc. | Systems and methods for evolving enzymes with desired activities |
WO2012038049A2 (en) * | 2010-09-22 | 2012-03-29 | Roche Diagnostics Gmbh | Amplification of distant nucleic acid targets using engineered primers |
TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
JP5851092B2 (ja) * | 2010-12-24 | 2016-02-03 | 株式会社明治 | ペプチド組成物、およびその製造方法 |
JP2014504503A (ja) | 2010-12-28 | 2014-02-24 | ゾーマ テクノロジー リミテッド | Pdzドメインを用いた細胞表面提示 |
US9528101B2 (en) | 2011-09-23 | 2016-12-27 | PHARMED ARTIS GmbH | Granzyme B protease variants |
CN104487572B (zh) * | 2012-05-25 | 2019-12-13 | 科.汉森有限公司 | 具有改善的凝乳性质的凝乳酶变体 |
EA028865B1 (ru) | 2012-07-25 | 2018-01-31 | Каталист Биосайенсиз, Инк. | Модифицированные полипептиды фактора х и их применение |
JP6306596B2 (ja) * | 2012-10-04 | 2018-04-04 | リサーチ ディベロップメント ファウンデーション | セリンプロテアーゼ分子および療法 |
CA2938015A1 (en) | 2014-02-26 | 2015-09-03 | Chr. Hansen A/S | Variants of chymosin with improved milk-clotting properties |
RU2710726C2 (ru) * | 2014-04-29 | 2020-01-10 | Новартис Аг | Новые клетки позвоночных и способы рекомбинантной экспрессии интересующего полипептида |
EP3237003B1 (en) | 2014-12-24 | 2021-08-11 | NexImmune, Inc | Nanoparticle compositions and methods for immunotherapy |
US11174473B2 (en) | 2015-06-22 | 2021-11-16 | Chr. Hansen A/S | Variants of chymosin with improved properties |
EP3344049A1 (en) | 2015-08-31 | 2018-07-11 | Chr. Hansen A/S | Variants of chymosin with improved properties |
WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
SG10202004259PA (en) | 2015-11-19 | 2020-06-29 | Asclepix Therapeutics Llc | Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations |
EP3411397A1 (en) | 2016-02-05 | 2018-12-12 | Orionis Biosciences NV | Cd8 binding agents |
EP4276114A3 (en) | 2016-03-07 | 2024-02-21 | Vib Vzw | Cd20 binding single domain antibodies |
CA3023883A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
WO2017198810A1 (en) | 2016-05-19 | 2017-11-23 | Chr. Hansen A/S | Variants of chymosin with improved milk-clotting properties |
MX2018013924A (es) | 2016-05-19 | 2019-03-28 | Chr Hansen As | Variantes de quimosina con propiedades mejoradas de coagulacion de leche. |
BR112019006735A2 (pt) | 2016-10-04 | 2019-06-25 | Asclepix Therapeutics Llc | compostos e métodos para ativação da sinalização de tie2 |
BR102017010169A2 (pt) * | 2017-05-15 | 2019-02-26 | Remer Consultores Assessoria Empresarial Ltda. | composto, intermediário de síntese, uso na preparação de anticonvulsivante, composição farmacêutica anticonvulsivante |
JP7204643B2 (ja) | 2016-10-24 | 2023-01-16 | オリオニス バイオサイエンシズ ビーブイ | 標的変異インターフェロン-ガンマおよびその使用 |
GB201622422D0 (en) * | 2016-12-30 | 2017-02-15 | Dublin Inst Of Tech | Peptide prediction |
CN110546160A (zh) | 2017-02-06 | 2019-12-06 | 奥里尼斯生物科学公司 | 靶向嵌合蛋白及其用途 |
WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
CA3067851C (en) | 2017-06-22 | 2023-01-31 | Catalyst Biosciences, Inc. | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use |
WO2019028427A1 (en) | 2017-08-03 | 2019-02-07 | Asclepix Therapeutics, Llc. | METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR |
CN108241054B (zh) * | 2017-12-26 | 2021-03-12 | 天津市中西医结合医院(天津市南开医院) | 检测g蛋白偶联受体18的试剂在制备败血症诊断及病程监测和预后判断试剂中表达的应用 |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
AU2019215440A1 (en) | 2018-02-05 | 2020-08-27 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
MX2021007843A (es) | 2018-12-28 | 2021-08-11 | Vertex Pharma | Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso. |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
EA202192146A1 (ru) | 2019-02-15 | 2021-11-09 | Интиграл Молекьюлар, Инк. | Антитела к клаудину 6 и их применение |
US11254736B2 (en) | 2019-02-15 | 2022-02-22 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
WO2020210455A1 (en) * | 2019-04-09 | 2020-10-15 | University Of Houston System | Engineered chymotrypsins and uses thereof |
CN110079514A (zh) * | 2019-04-12 | 2019-08-02 | 江苏大学 | 一种制备蛋白酶3重组蛋白的方法 |
US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
GB202004514D0 (en) | 2020-03-27 | 2020-05-13 | Inst De Medicina Molecular Joaeo Lobo Antunes | Treatment of Immunosuppressive Cancer |
CN112322722B (zh) * | 2020-11-13 | 2021-11-12 | 上海宝藤生物医药科技股份有限公司 | 检测16p11.2微缺失的引物探针组合物、试剂盒及其应用 |
WO2024008755A1 (en) | 2022-07-04 | 2024-01-11 | Vib Vzw | Blood-cerebrospinal fluid barrier crossing antibodies |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185258A (en) * | 1984-05-29 | 1993-02-09 | Genencor International, Inc. | Subtilisin mutants |
US5801038A (en) * | 1984-05-29 | 1998-09-01 | Genencor International Inc. | Modified subtilisins having amino acid alterations |
DK6488D0 (da) * | 1988-01-07 | 1988-01-07 | Novo Industri As | Enzymer |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5304482A (en) * | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
US5843693A (en) * | 1989-08-16 | 1998-12-01 | Chiron Corporation | Assay method for screening for inhibitors of proTNF conversion |
US6271012B1 (en) * | 1989-10-11 | 2001-08-07 | Genencor International, Inc. | Protease muteins and their use in detergents |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5766842A (en) * | 1994-09-16 | 1998-06-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of a protein to a drug targeted thereagainst |
US6165794A (en) * | 1994-11-10 | 2000-12-26 | The Regents Of The University Of California | Suppression of proteolytic activity by dysfunctional protease formation |
GB9618960D0 (en) * | 1996-09-11 | 1996-10-23 | Medical Science Sys Inc | Proteases |
US6969601B2 (en) * | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
DE19743683A1 (de) * | 1997-10-02 | 1999-04-08 | Basf Ag | Verfahren zur Änderung der Substratspezifität von Enzymen |
US20030186329A1 (en) * | 1999-03-22 | 2003-10-02 | The Scripps Research Institute | Use of substrate subtraction libraries to distinguish enzyme specificities |
US20020068320A1 (en) * | 2000-03-14 | 2002-06-06 | Yanggu Shi | Serine protease polynucleotides, polypeptides, and antibodies |
DE19943177C2 (de) * | 1999-09-09 | 2002-10-24 | Dieter Jenne | Verfahren zur Herstellung von aktiven Serienproteasen und inaktiven Varianten |
US7030231B1 (en) * | 1999-09-30 | 2006-04-18 | Catalyst Biosciences, Inc. | Membrane type serine protease 1 (MT-SP1) and uses thereof |
US20030171252A9 (en) * | 2000-01-31 | 2003-09-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
JP2003521938A (ja) * | 2000-02-11 | 2003-07-22 | イーライ・リリー・アンド・カンパニー | プロテインc誘導体 |
US20020031801A1 (en) * | 2000-03-24 | 2002-03-14 | Millennium Pharmaceuticals, Inc. | 18806, a novel trypsin serine protease-like molecule and uses thereof |
US6680178B2 (en) * | 2000-06-02 | 2004-01-20 | The Regents Of The University Of California | Profiling of protease specificity using combinatorial fluorogenic substrate libraries |
US7157596B2 (en) * | 2000-09-08 | 2007-01-02 | Dendreon Corporation | Inhibitors of serine protease activity of matriptase or MTSP1 |
US6797461B2 (en) * | 2000-10-27 | 2004-09-28 | Promega Corporation | Tryptase substrates and assay for tryptase activity using same |
US20030104591A1 (en) * | 2000-12-14 | 2003-06-05 | Murray Christopher J. | Methods and compositions for grafting functional loops into a protein |
US20030068792A1 (en) * | 2000-12-14 | 2003-04-10 | Yiyou Chen | Targeted enzymes |
US20030049689A1 (en) * | 2000-12-14 | 2003-03-13 | Cynthia Edwards | Multifunctional polypeptides |
US20030199038A1 (en) * | 2002-04-22 | 2003-10-23 | Novozymes Biotech, Inc. | Method for preparing polypeptide variants |
US20040072276A1 (en) * | 2002-05-10 | 2004-04-15 | Direvo BioTech AG. | Process for generating sequence-specific proteases by directed evolution and use thereof |
EP1539941A4 (en) * | 2002-08-27 | 2006-11-29 | ADZYMES AND THEIR USES | |
EP1539960B1 (en) * | 2002-09-09 | 2010-04-28 | Hanall Pharmaceutical Co., Ltd. | Protease-resistant modified interferon alpha polypeptides |
US7939304B2 (en) * | 2002-10-02 | 2011-05-10 | Catalyst Biosciences, Inc. | Mutant MT-SP1 proteases with altered substrate specificity or activity |
ZA200502867B (en) * | 2002-10-02 | 2007-09-26 | Catalyst Biosciences Inc | Methods of generating and screening for proteases with altered specificity |
US20060024289A1 (en) * | 2002-10-02 | 2006-02-02 | Ruggles Sandra W | Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases |
US20040115727A1 (en) * | 2002-12-11 | 2004-06-17 | Allergan, Inc., A Corporation | Evolved clostridial toxins with altered protease specificity |
US7335504B2 (en) * | 2003-06-18 | 2008-02-26 | Direvo Biotechnology Ag | Engineered enzymes and uses thereof |
US20050002897A1 (en) * | 2003-06-18 | 2005-01-06 | Ulrich Haupts | Biological entities and the pharmaceutical or diagnostic use thereof |
US7439226B2 (en) * | 2003-09-30 | 2008-10-21 | The United States Of America As Represented By The Department Of Health And Human Services | Serine protease inhibitors |
AU2005244271B2 (en) * | 2004-04-12 | 2010-04-08 | Vertex Pharmaceuticals Incorporated | Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1 |
EP1726643A1 (en) * | 2005-05-27 | 2006-11-29 | Direvo Biotech AG | Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances |
US7974395B2 (en) * | 2005-09-28 | 2011-07-05 | Avaya Inc. | Detection of telephone number spoofing |
MX2008004693A (es) * | 2005-10-21 | 2008-09-03 | Catalyst Biosciences Inc | Proteasas modificadas que inhiben la activacion del complemento. |
CN101374856A (zh) * | 2005-11-29 | 2009-02-25 | 斯克里普斯研究学院 | 抑制肿瘤细胞浸润、转移和血管生成 |
DK2046951T5 (da) * | 2006-07-05 | 2012-01-23 | Catalyst Biosciences Inc | Proteasesreeningsmetoder og proteaser identificeret dermed |
EP2147096B1 (en) * | 2007-04-13 | 2015-03-25 | Catalyst Biosciences, Inc. | Modified factor VII polypeptides and uses thereof |
TWI557135B (zh) * | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
-
2003
- 2003-10-02 ZA ZA200502867A patent/ZA200502867B/xx unknown
- 2003-10-02 KR KR1020107018921A patent/KR20100109969A/ko not_active Application Discontinuation
- 2003-10-02 SG SG200704897-8A patent/SG166001A1/en unknown
- 2003-10-02 MX MXPA05003493A patent/MXPA05003493A/es active IP Right Grant
- 2003-10-02 US US10/677,977 patent/US20040146938A1/en not_active Abandoned
- 2003-10-02 CN CNA2003801026530A patent/CN101124484A/zh active Pending
- 2003-10-02 KR KR1020057005800A patent/KR101132555B1/ko not_active IP Right Cessation
- 2003-10-02 NZ NZ590187A patent/NZ590187A/en not_active IP Right Cessation
- 2003-10-02 SG SG2009070467A patent/SG188669A1/en unknown
- 2003-10-02 EP EP03774608A patent/EP1608947A4/en not_active Withdrawn
- 2003-10-02 NZ NZ539242A patent/NZ539242A/en not_active IP Right Cessation
- 2003-10-02 WO PCT/US2003/031719 patent/WO2004031733A2/en active Application Filing
- 2003-10-02 KR KR1020127014802A patent/KR20120088836A/ko not_active Application Discontinuation
- 2003-10-02 JP JP2004541703A patent/JP5376747B2/ja not_active Expired - Fee Related
- 2003-10-02 CN CN201510012744.XA patent/CN104630192A/zh active Pending
- 2003-10-02 EP EP11179703A patent/EP2444810A3/en not_active Withdrawn
- 2003-10-02 EP EP11179700.7A patent/EP2444809A3/en not_active Withdrawn
- 2003-10-02 AU AU2003282724A patent/AU2003282724B2/en not_active Ceased
- 2003-10-02 CA CA002501295A patent/CA2501295A1/en not_active Abandoned
-
2005
- 2005-04-29 NO NO20052096A patent/NO20052096L/no not_active Application Discontinuation
-
2007
- 2007-12-28 US US12/005,949 patent/US20090136477A1/en not_active Abandoned
-
2009
- 2009-12-16 JP JP2009285529A patent/JP2010099082A/ja active Pending
-
2010
- 2010-03-25 AU AU2010201204A patent/AU2010201204B2/en not_active Ceased
-
2012
- 2012-07-10 JP JP2012154952A patent/JP2012254988A/ja active Pending
Non-Patent Citations (2)
Title |
---|
DEFINITION AND REDESIGN OF THE EXTENDED SUBSTRATE SPECIFICITY OF GRANZYME B * |
IMPROVED BIOCATALYSTS BY DIRECTED EVOLUTION AND RATIONAL PROTEIN DESIGN * |
Also Published As
Publication number | Publication date |
---|---|
EP2444810A2 (en) | 2012-04-25 |
AU2010201204B2 (en) | 2012-09-20 |
JP2010099082A (ja) | 2010-05-06 |
EP2444809A3 (en) | 2013-07-24 |
NO20052096L (no) | 2005-06-28 |
EP2444810A3 (en) | 2013-01-02 |
US20040146938A1 (en) | 2004-07-29 |
JP5376747B2 (ja) | 2013-12-25 |
KR20050083717A (ko) | 2005-08-26 |
EP2444809A2 (en) | 2012-04-25 |
WO2004031733A3 (en) | 2007-03-15 |
MXPA05003493A (es) | 2005-09-30 |
US20090136477A1 (en) | 2009-05-28 |
NZ590187A (en) | 2012-07-27 |
AU2003282724B2 (en) | 2010-03-04 |
NZ539242A (en) | 2009-07-31 |
KR20100109969A (ko) | 2010-10-11 |
KR20120088836A (ko) | 2012-08-08 |
CN104630192A (zh) | 2015-05-20 |
KR101132555B1 (ko) | 2012-04-02 |
ZA200502867B (en) | 2007-09-26 |
CA2501295A1 (en) | 2004-04-15 |
AU2003282724A1 (en) | 2004-04-23 |
EP1608947A4 (en) | 2009-06-17 |
SG188669A1 (en) | 2013-04-30 |
WO2004031733A2 (en) | 2004-04-15 |
JP2006518983A (ja) | 2006-08-24 |
EP1608947A2 (en) | 2005-12-28 |
JP2012254988A (ja) | 2012-12-27 |
NO20052096D0 (no) | 2005-04-29 |
CN101124484A (zh) | 2008-02-13 |
AU2010201204A1 (en) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG166001A1 (en) | Methods of generating and screening for proteases with altered specificity | |
DE69931377D1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
TW200745552A (en) | HU-ASP 1 protease substrate and uses thereof | |
MX342777B (es) | Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa. | |
WO2005100556A3 (en) | Cleavage of vegf and vegf receptor by wild-type and mutant proteases | |
WO2006071469A3 (en) | Modulation of the neuroendocrine system as a therapy for amyotrophic lateral sclerosis | |
HK1016495A1 (en) | Phosphorous-containing cysteine and serine protease inhibitors | |
HK1025511A1 (en) | Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors | |
WO1996024650A3 (en) | Cytoplasmic antiproteinase-2 and cytoplasmic antiproteinase-3 and coding sequences | |
WO2003095475A8 (en) | Peptide compounds and their use as protease substrates | |
SG158739A1 (en) | Aggrecanase molecules | |
DE69825733D1 (de) | Spezifische inhibitoren der pankreatischen lipase und deren anwendungen | |
WO2002014264A3 (en) | (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production | |
Murayama et al. | The unusual high molecular mass of Bothrops protease A, a trypsin-like serine peptidase from the venom of Bothrops jararaca, is due to its high carbohydrate content | |
ATE338814T1 (de) | Verfahren zur kultivierung von zellen und zur vermehrung von viren | |
AU2003247599A1 (en) | Methods of modulating cytokinin related processes in a plant using b3 domain proteins | |
EP1385993B8 (en) | Method of detecting and treating tuberous sclerosis complex associated disorders | |
DE60121815D1 (de) | System und prozess zur reinigung und/oder behandlung von fahrzeugoberflächen | |
ATE274599T1 (de) | Verfahren zur enzymatischen racematspaltung von aminomethyl-aryl-cyclohexanol-derivaten | |
DE60334316D1 (de) | Frpb proteinmutante und verfahren zur erneuten faltung | |
DE60331414D1 (de) | Aggrecanase-1- und -2-peptidsubstrate und verfahren | |
BR0314120A (pt) | Processo para a diminuição dos nìveis de agregado de proteìna peguilada | |
WO2002100333A3 (en) | Inhibitors of reggamma | |
WO2002081665A3 (en) | Implantation serine proteinases | |
NZ525368A (en) | Novel aggrecanase molecules |